Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis
Hideaki Tsuji,Ran Nakashima,Yuji Hosono,Yoshitaka Imura,Masato Yagita,Hajime Yoshifuji,Shintaro Hirata,Takaki Nojima,Eiji Sugiyama,Kazuhiro Hatta,Yoshio Taguchi,Masaki Katayama,Kiminobu Tanizawa,Tomohiro Handa,Ryuji Uozumi,Shuji Akizuki,Kosaku Murakami,Motomu Hashimoto,Masao Tanaka,Koichiro Ohmura,Tsuneyo Mimori
DOI: https://doi.org/10.1002/art.41105
2020-01-27
Abstract:<h3 class="article-section__sub-title section1"> Objective</h3><p>Interstitial lung disease (ILD) accompanied by anti‐melanoma differentiation‐associated gene 5 (MDA5)‐positive dermatomyositis (DM) is often rapidly progressive and associated with poor prognosis. Because there is no established treatment, we prospectively evaluated the efficacy and safety of a combined immunosuppressive regimen for anti‐MDA5‐positive DM with ILD.</p><h3 class="article-section__sub-title section1"> Methods</h3><p>Adult Japanese patients with newly onset anti‐MDA5‐positive DM with ILD (n = 29) were enrolled in multiple centers from 2014 to 2017. They were treated with a regimen of high‐dose glucocorticoids (GC), tacrolimus, and intravenous cyclophosphamide (IVCY). Plasmapheresis was used if patients worsened after the regimen started. The primary endpoint was six‐month survival, compared with that of a historical control (n = 15) of patients with anti‐MDA5‐positive DM with ILD who received step‐up treatment (high‐dose GC and stepwise addition of immunosuppressant). Secondary endpoints were 12‐month survival rate, adverse events, and changes in laboratory data.</p><h3 class="article-section__sub-title section1"> Results</h3><p>The combined immunosuppressive regimen group showed significantly higher 6‐month survival than the step‐up treatment group (89% and 33%, respectively, P < 0.0001). Over 52 weeks, anti‐MDA5 titer, serum ferritin level, percent vital capacity, and chest high‐resolution computed tomography scores improved. The combined immunosuppressive regimen group received IVCY nearly 20 days earlier with shorter intervals and tended to receive plasmapheresis more often than patients undergoing step‐up treatment (n = 15). Cytomegalovirus reactivation was frequently observed over 52 weeks.</p><h3 class="article-section__sub-title section1"> Conclusion</h3><p>A combined immunosuppressive regimen is effective for anti‐MDA5‐positive DM with ILD. Plasmapheresis can be used for additional effect in intractable disease. Opportunistic infections should be carefully monitored during treatment.</p>
rheumatology